



# LUND UNIVERSITY

## Effects of TNFalpha on the human nasal mucosa in vivo.

Widegren, Henrik; Korsgren, Magnus; Andersson, Morgan; Greiff, Lennart

*Published in:*  
Respiratory Medicine

*DOI:*  
[10.1016/j.rmed.2007.04.005](https://doi.org/10.1016/j.rmed.2007.04.005)

2007

[Link to publication](#)

*Citation for published version (APA):*

Widegren, H., Korsgren, M., Andersson, M., & Greiff, L. (2007). Effects of TNFalpha on the human nasal mucosa in vivo. *Respiratory Medicine*, 101(9), 1982-1987. <https://doi.org/10.1016/j.rmed.2007.04.005>

*Total number of authors:*  
4

### General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00





LUND UNIVERSITY  
Faculty of Medicine

---

# LU:*research*

*Institutional Repository of Lund University*

---

This is an author produced version of a paper published in Respiratory medicine. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Citation for the published paper:  
Widegren, Henrik and Korsgren, Magnus and  
Andersson, Morgan and Greiff, Lennart.  
"Effects of TNFalpha on the human nasal mucosa  
in vivo."

Respir Med, 2007, Vol: 101, Issue: 9, pp. 1982-7.

<http://dx.doi.org/doi:10.1016/j.rmed.2007.04.005>

Access to the published version may  
require journal subscription.  
Published with permission from: Elsevier

# Effects of TNF $\alpha$ on the human nasal mucosa *in vivo*

Henrik Widegren<sup>1</sup>, Magnus Korsgren<sup>2</sup>, Morgan Andersson<sup>1</sup>, Lennart Greiff<sup>1</sup>

Department of Otorhinolaryngology, Head & Neck Surgery<sup>1</sup> and Clinical Pharmacology<sup>2</sup>, Lund University Hospital, Lund, Sweden

Correspondence: Lennart Greiff, MD

Department of Otorhinolaryngology, Head & Neck Surgery  
Lund University Hospital  
SE-221 85 Lund Sweden

E-mail: [lennart.greiff@skane.se](mailto:lennart.greiff@skane.se)

Fax: +46-46-211 09 69

Tel: +46-46-17 10 00

Running head: Effects of TNF $\alpha$  on the nasal mucosa

## Abstract

**Background:** TNF $\alpha$  is a cytokine that may contribute to the pathophysiology of airway inflammation. Inhalation of TNF $\alpha$  produces granulocyte recruitment and airway hyper-responsiveness in man. Anti-TNF $\alpha$  treatment may inhibit allergen-induced plasma exudation in guinea-pig airways. Increased nasal mucosal output of TNF $\alpha$  has been demonstrated in allergic rhinitis, but the effect of TNF $\alpha$  on the human nasal mucosa has not been examined *in vivo*.

**Objective:** To examine effects of topical TNF $\alpha$  on the human nasal mucosa *in vivo*.

**Methods:** In a dose-finding study, healthy subjects received intranasal TNF $\alpha$  (0-7.5  $\mu$ g). Nasal lavages were carried out before as well as 10 min and 24 hrs post challenge and  $\alpha_2$ -macroglobulin was measured as an index of plasma exudation. In a second study, involving patients with allergic rhinitis examined out of season, a sham-controlled nasal challenge with TNF $\alpha$  (10  $\mu$ g) was performed and followed 24 hrs later by an allergen challenge. Lavages were performed before the TNF $\alpha$  challenge, 24 hrs thereafter, and 10 min post allergen challenge.  $\alpha_2$ -Macroglobulin, eosinophil cationic protein (ECP), myeloperoxidase (MPO), and IL-8 were analyzed as indices of plasma exudation, eosinophil activity, neutrophil activity, and pro-inflammatory cytokine production, respectively.

**Results:** In the dose-finding study, TNF $\alpha$  produced significant increases in  $\alpha_2$ -macroglobulin 24 hrs post challenge ( $p < 0.01$ ). In allergic rhinitis, 10  $\mu$ g of TNF $\alpha$  also produced this effect ( $p < 0.01$ ) as well as increases in ECP and IL-8 ( $p < 0.01$ ). MPO was increased 24 hrs post challenge, but this change did not reach statistical significance. TNF $\alpha$  did not produce any acute effects and did not affect the responsiveness to allergen.

**Conclusion:** The present study demonstrates that topical TNF $\alpha$  produces a human nasal inflammatory response. These data suggest a role of TNF $\alpha$  in nasal conditions characterised by mucosal inflammation.

**Key words:** Eosinophils, exudation, inflammation, IL-8, neutrophils.

## Introduction

TNF $\alpha$  is a pro-inflammatory mediator involved in the pathophysiology of a range of inflammatory conditions. Frequently explored areas are autoimmune conditions such as rheumatoid arthritis and Crohn's disease, which today are successfully treated with TNF $\alpha$ -inhibitors [1].

The role of TNF $\alpha$  in conditions characterized by airway inflammation is currently under investigation focusing on the bronchial airways. Yu *et al.* have shown increased bronchoalveolar lavage (BAL) cell expression of TNF $\alpha$  mRNA following airway allergen challenge in allergic mice [2]. Inhalation of TNF $\alpha$  in rats has been demonstrated to produce BAL neutrophilia and airway hyperresponsiveness [3]. In experimental models of asthma, blockade of TNF $\alpha$  activity has been shown to reduce allergen-induced airway extravasation of plasma and granulocyte recruitment [2, 4-6]. In human bronchial airways, TNF $\alpha$  is produced by a number of cell types, including macrophages [7], eosinophils [8, 9], epithelial cells [10, 11], and mast cells [12, 13]. Inhalation of TNF $\alpha$  produces an inflammatory response characterized by increased sputum numbers of neutrophils and eosinophils as well as by development of airway hyperresponsiveness [14, 15]. Furthermore, recent studies have shown that treatment with etanercept, a soluble TNF $\alpha$  receptor-IgG1 Fc fusion protein, is associated with improvement in asthma symptoms, lung function, and airway hyperresponsiveness in refractory asthma [16, 17].

Potentially reflecting the pathophysiological similarities between airway inflammation in allergic rhinitis and asthma, patients suffering from allergic rhinitis have been shown to feature increased tissue expression of TNF $\alpha$  mRNA as well as increased nasal mucosal output of the TNF $\alpha$  protein [18-20]. However, information on the role of TNF $\alpha$  in human nasal airways is limited. Notably, to the best of our knowledge, there is no information on the consequences to the nasal airway and to allergic rhinitis of increased TNF $\alpha$  activity. One way of exploring this, again in analogy with the bronchial airways [14, 15], would be to examine effects of TNF $\alpha$  topically applied on the nasal mucosa.

In the present study, we have thus examined effects of topical TNF $\alpha$  on the human nasal mucosa. First, increasing doses were given to healthy subjects, and nasal symptoms and PIF (peak inspiratory flow) were monitored. Also, nasal lavages were carried out and levels of  $\alpha_2$ -macroglobulin were monitored as an index of plasma exudation. Secondly, an exudation-producing dose of TNF $\alpha$  was given to patients with seasonal allergic rhinitis (out of season). Nasal lavages were carried out 24 hrs post challenge and lavage fluid levels of  $\alpha_2$ -macroglobulin, eosinophil cationic protein (ECP), myeloperoxidase (MPO), and interleukin-8 (IL-8) were measured as indices of inflammation. In addition, a nasal allergen challenge was carried out immediately after the 24 hrs lavage, and this measure was also followed by a lavage and again by analysis of  $\alpha_2$ -macroglobulin, ECP, MPO, and IL-8. The rationale for employing an allergen challenge was that patients with allergic rhinitis often feature a variable responsiveness to allergen depending of the underlying inflammatory activity. Accordingly, we hypothesized that an inflammatory effect of TNF $\alpha$  could change the responsiveness to allergen.

# Material and methods

## Study design

Subjects were challenged intranasally with TNF $\alpha$ . Healthy individuals were recruited to a dose-finding study and, subsequently, patients with allergic rhinitis were recruited to a principal study. Written informed consent was obtained and the study was approved by the regional ethics committee.

### *Dose-finding study*

Ten healthy volunteers (9 males, 1 female) aged between 18 and 27 participated in the study. Prior to the first challenge all subjects were subjected to an interview, a general health examination, a nasal examination, and a skin prick test. Inclusion criteria were: A negative skin prick test, a normal nasal examination, and use of contraceptives (for females). Exclusion criteria were: A history of upper respiratory tract infection within a period of seven days before the start of the study, allergic and non-allergic rhinitis, other nasal disease (structural abnormalities, rhinosinusitis, nasal polyposis), use of nasal decongestants within a period of seven days before the start of the study, other pharmacological treatments (except occasional analgesics) within a period of one month prior to the study.

Intranasal challenges with isotonic saline and escalating doses of TNF $\alpha$  were carried out. The doses of TNF $\alpha$  were 0.3, 1.5, and 7.5  $\mu$ g, and between the challenges washout periods of seven days were instituted. Nasal lavages were carried out 5 min before, 10 min after, and 24 hrs after every challenge. Also, two 30 sec lavages were carried out immediately prior to the TNF $\alpha$  challenge (these lavages were employed to produce a low baseline and were not collected). Nasal lavage levels of  $\alpha_2$ -macroglobulin were measured as an index of plasma exudation. Prior to each nasal lavage the subjects scored nasal symptoms and monitored nasal PIF (peak inspiratory flow) using a specific flow meter (Clement-Clarke, Harlow, UK). Sneezes, secretion, and blockage were each scored on a scale from 0-3. The scores were added to a total nasal symptom score (range 0-9).



### *Principal study*

Sixteen patients with allergic rhinitis (11 males, 5 females) aged between 24 and 35 participated in the study. All subjects were subjected to an interview, a general health examination, a nasal examination, and a skin prick test. Inclusion and exclusion criteria were the same as described above except that these subjects presented a history of at least two years of seasonal allergic rhinitis and a positive skin prick test to relevant aeroallergens.

Nasal spray-challenges with 10 µg of TNFα and isotonic saline were carried out in a crossover, randomized, and sham-controlled design. A washout period of two weeks was instituted between the challenges. Twenty-four hours after each challenge, the patients were subjected to a nasal allergen challenge (1,000 SQ-U of either birch or grass pollen allergen). Nasal saline lavages were carried out 5 min before each TNFα challenge, 24 hrs thereafter (just before the allergen challenge), and 10 min after each allergen challenge. Also, two 30 sec lavages were carried out immediately prior to the TNFα challenge (these lavages were not collected). Nasal lavage levels of α<sub>2</sub>-macroglobulin, IL-8, ECP, and MPO, and were measured as indices of plasma exudation, pro-inflammatory cytokine production, eosinophil activity, and neutrophil activity, respectively. Prior to the challenge, 24 hrs after sham/TNFα challenge, and 10 min following the allergen challenge sneezes, secretion, and blockage were scored as described above.

### **TNFα challenge and nasal lavages**

Recombinant human TNFα (210-TA/CF, R&D Systems, Abingdon, UK) was mixed with isotonic saline to concentrations where 100 µl of each solution contained the preferred amounts of TNFα. The TNFα-solution was prepared less than one hour before the challenge and it was administered using a spray-device delivering 100 µl per actuation. At all times the challenges and lavages were administered to the right hand side nasal cavity. The lavages were carried out using a pool-device containing 15 ml of isotonic saline [21]. The lavage fluids were kept in the right nasal cavity for 5 min. The recovered lavage fluid was centrifuged and the supernatant was homogenized, prepared in aliquots, and frozen (-30°C) for later analysis.

## Analyses

$\alpha_2$ -Macroglobulin was measured using a radioimmunoassay sensitive to 7.8 ng/ml. Rabbit anti-human  $\alpha_2$ -macroglobulin (Dakopatts, Copenhagen, Denmark) was used as anti-serum and human serum (Behringwerke, Marburg, Germany) as standard. Human  $\alpha_2$ -macroglobulin (Capell-Organon, Turnhout, Belgium) was iodinated using a lactoperoxidase method. Tracer and standard/sample was mixed with antiserum before adding goat anti-rabbit anti-serum (AstraZeneca, Lund, Sweden). The bound fraction was measured using a gamma counter. The intra- and inter- assay coefficients of variation were between 3.8-6.0% and 3.1-7.2%, respectively. IL-8 was measured using a commercially available enzyme-linked immunosorbent assay (R&D Systems, Abingdon, UK). ECP and MPO were also measured using commercially available assays (Pharmacia, Uppsala, Sweden). The limits of detection for IL-8, ECP, and MPO were 31.2 pg/ml, 2.0 ng/ml, and 1.6 ng/ml, respectively.

## Statistics

In healthy subjects, differences in levels of  $\alpha_2$ -macroglobulin between observation at different TNF $\alpha$  doses were analysed by the Friedman test and, if statistical significance was achieved, by the Wilcoxon signed rank test. In patients with allergic rhinitis, differences in symptoms and lavage fluid levels of  $\alpha_2$ -macroglobulin, IL-8, ECP, and MPO were analysed using the Wilcoxon signed rank test. A p-value of <0.05 was considered significant. Data are presented as mean $\pm$ SEM.

## Results

In the dose-finding study, intranasal challenge with TNF $\alpha$  produced a significant increase in lavage fluid levels of  $\alpha_2$ -macroglobulin as recorded 24 hrs post challenge ( $p<0.01$ ). In contrast, no such effect was observed 10 min post challenge (Fig. 1). No significant changes in nasal symptoms or nasal PIF were observed at any time point or at any challenge dose (data not shown).

In patients with allergic rhinitis, challenge with 10  $\mu$ g of TNF $\alpha$  produced significant increases in lavage levels of  $\alpha_2$ -macroglobulin 24 hrs post challenge (*c.f.* sham challenge) (Fig 2a). In addition, significant increases were observed for IL-8 and ECP at this time point (Figs. 2b and c). Nasal lavage fluid levels of MPO were also increased 24 hrs post challenge, but this change failed to reach statistical significance ( $p=0.09$ ) (Fig. 2d). TNF $\alpha$  produced low-grade nasal symptoms 24 hrs post challenge (*c.f.* sham challenge) (Table I).

In sham challenged subjects, levels of  $\alpha_2$ -macroglobulin were significantly increased 10 min post allergen challenge, compared with pre allergen challenge (24 hrs) levels ( $p<0.01$ ). Also, the allergen challenge produced significant nasal symptoms (Table I): score 5 out of 9 ( $p<0.001$ ).

The symptom score recorded post allergen challenge was not affected by TNF $\alpha$  administration 24 hrs earlier (Table I). Similarly, with the exception of MPO, the lavage fluid indices recorded post allergen challenge were unaffected by prior TNF $\alpha$  administration (*c.f.* sham challenge) (Fig 2a-d). Post allergen challenge MPO levels increased significantly following TNF $\alpha$  administration ( $p<0.05$ ) (*c.f.* sham challenge) (Fig 2d).

In the principal study, at the 24 hour observation (i.e., the point in time when the effect of TNF $\alpha$  was compared to the sham challenge) the overall percentage of nasal lavages with levels of IL-8, ECP, and MPO below the limit of detection was 0, 19, and 0%, respectively.

## Discussion

The present study, involving healthy subjects as well as patients with allergic rhinitis, has shown that TNF $\alpha$  produces plasma exudation when applied topically onto the nasal mucosa. This response is associated with pro-inflammatory cytokine production (IL-8) and increased granulocyte activity. The observations are of interest in the context of viewing TNF $\alpha$  as a mediator of potential importance to nasal airway defence as well as to the pathophysiology of nasal conditions characterised by inflammation.

The selection of the first dose of the present challenge-series was based on a study by Thomas *et al.* in which humans inhaled 60 ng of TNF $\alpha$  to the lower airways [14]. At this dose-level, none of eight subjects were reported to experience symptoms suggestive of systemic effects, whereas the authors observed a leftward shift in the dose-response curve to methacholine and a significant rise in the levels of polymorphonuclear cells in sputum. For safety reasons we examined healthy subjects first: As we increased the dose of TNF $\alpha$  from 0.3 to 7.5  $\mu$ g all subjects remained symptomless and no adverse events occurred. For our principal study, involving patients with allergic rhinitis, 10  $\mu$ g of TNF $\alpha$  was chosen as challenge dose to assure a positive response. This dose produced only low-grade nasal symptoms (score about 1 on a scale from 0 to 9) and no adverse effect. Accordingly, we conclude that TNF $\alpha$  in the present dose-range is safe as an experimental, nasal challenge agent.

Based on preliminary observations on acute plasma exudation producing effects of TNF $\alpha$  in guinea-pig airways (Greiff *et al.*, unpubl.), suggesting that TNF $\alpha$  may act as a direct microvascular permeability increasing mediator, we selected nasal lavage fluid levels of the plasma protein  $\alpha_2$ -macroglobulin as index in our dose-finding study [22]. We could demonstrate that TNF $\alpha$  induced plasma exudation in the human nasal airway. However, whereas TNF $\alpha$  produced this effect 24 hrs post challenge, no plasma exudation was observed acutely (10 min post challenge). Our observation suggests species differences between humans and rodents. Such differences have previously been shown and may be attributable to a differential ability of sensory nerves to evoke and mediate exudative, neurogenic inflammation [22]. We can not exclude that even higher

doses of TNF $\alpha$  would have produced acute plasma exudation in our challenge model. However, the present observation suggests that TNF $\alpha$ -induced plasma exudation 24 hrs post challenge does not reflect a direct microvascular action of the mediator, but rather a secondary response to increased cellular inflammation (below). Our finding suggests the possibility that TNF $\alpha$  can be a pro-inflammatory mediator in the human nasal airway.

In the present study, the nasal output of ECP and MPO was increased 24 hrs post TNF $\alpha$  challenge. Whereas this effects was statistically significant for ECP, it reached borderline significance for MPO ( $p=0.09$ ). In addition to ECP and MPO, the output of the pro-inflammatory chemokine IL-8 was also increased. These findings are in keeping with observations in man on increased numbers of granulocytes in sputum following TNF $\alpha$  inhalation [14]. It is also in agreement with reports showing that treatment with a soluble TNF $\alpha$  receptor, reducing the levels of free TNF $\alpha$ , attenuates peribronchial eosinophil and neutrophil infiltration in allergic mice [4]. Furthermore, our data support *in vitro* findings by Yamagishi *et al.* on reduced epithelial cell production of IL-8 following TNF $\alpha$ -antibody treatment [23]. Taken together, available data suggest that TNF $\alpha$  is involved in mounting airway granulocyte responses, in part through increased IL-8 activity [24], and that this mechanism is valid also for the human nasal airway. Additional studies are warranted to further explore this effect of TNF $\alpha$  and tentatively such approaches should comprise lavage as well as tissue observations.

The present allergen challenge performed 24 hrs post sham challenge produced symptoms of allergic rhinitis as well as significant plasma exudation. These responses, and the employed lavage fluid indices with the exception of MPO, were not significantly affected by TNF $\alpha$  administration (*c.f.* sham challenge). Our observations suggest the possibility that TNF $\alpha$  may not be critically involved in the pathophysiology of allergen responsiveness in allergic rhinitis. Somewhat in contrast, Thomas *et al.* [14, 15] demonstrated increased airway responsiveness to methacholine 24 hours after inhalation of TNF $\alpha$  in normal subjects as well as in mild asthmatics. Furthermore, Renzetti *et al.* reported that pre-treatment of allergic guinea-pigs with an anti-TNF $\alpha$ -agent reduced the airway responsiveness to substance P [6]. Differences between

challenge agents (allergen vs. methacholine/substance P), between nasal and bronchial airways, and between species may explain the above discrepancies. Also, we can not exclude that a greater dose of TNF $\alpha$  would have produced a different result in the present study. The strength of our observation lies in the fact that it involves humans and a clean, acute type-1 allergic reaction, as opposed to a more complex inflammatory condition that characterises asthma. Further studies, tentatively comprising anti-TNF $\alpha$  measures, are warranted to explore whether or not TNF $\alpha$  has a role in allergic rhinitis.

Our observation that levels of MPO recorded post allergen challenge was significantly increased by TNF $\alpha$  may suggest a development of “hyperresponsiveness”, in this case a situation where the nasal mucosa is prone to mount a neutrophil response. However, the allergen challenge may not *per se* have produced the increase in neutrophil activity. Alternatively, it may be speculated that TNF $\alpha$  *per se* produced a limited neutrophil degranulation, as suggested by the present study, and that the luminal entry of MPO was facilitated by the allergen-induced plasma exudation response. Such a mechanism has previously been demonstrated for other inflammatory mediators [22]. Further studies involving additional neutrophil markers and detailed analyses of nasal biopsies are needed to clarify this issue.

A study involving patients with allergic rhinitis examined out of season has shown that treatment with a clinical dose of an antihistamine (fexofenadine) may not affect elevated levels of TNF $\alpha$  in nasal secretions observed following nasal allergen-challenge [20]. Similarly, Benson *et al.* have demonstrated that a topical corticosteroid (budesonide) does not reduce the levels of TNF $\alpha$  in nasal fluids obtained from children with seasonal allergic rhinitis [25]. In the context of viewing anti-TNF $\alpha$  drugs as treatment candidates for airway conditions characterised by allergic airway inflammation, it is of interest to note that TNF $\alpha$  production may be little affected by such key anti-allergy pharmaceuticals. Accordingly, drugs that reduce TNF $\alpha$  activities may add to current airway therapeutic approaches. A role for anti-TNF $\alpha$  in the treatment of inflammatory airway conditions is suggested by the present observations and by other airway observations on pro-inflammatory effects of TNF $\alpha$  as well as by recent reports of

beneficial effects of anti-TNF $\alpha$  treatment in asthma [14-17]. A role in allergic inflammation may not be excluded by the present observation that TNF $\alpha$  (*c.f.* sham challenge) did not affect the response to an allergen challenge since the dose-response relationship, as well as the time-response relationship, has not been fully explored. Whether or not TNF $\alpha$  inhibiting drugs have a role in the treatment of nasal conditions characterised by inflammation, including allergic rhinitis, remains to be clarified.

We conclude that TNF $\alpha$  produces pro-inflammatory effects in human nasal airways, but that TNF $\alpha$  may not affect the responsiveness to allergen.

## Acknowledgement

We thank Mrs. L. Glantz-Larsson and Mrs. C. Cervin-Hoberg for technical assistance. The study was supported in parts by grants from the Swedish Research Council, Skåne County Council, and Lund University.



## Tables

Table I. Nasal symptom scores (mean $\pm$ SEM, range 0-9) recorded prior to any challenge, 24 hrs after sham/TNF $\alpha$  challenge, and following allergen challenge (performed 24 hrs after the sham/TNF $\alpha$  challenge). TNF $\alpha$  produced low-grade but significant symptoms (*c.f.* sham challenge). Allergen produced marked symptoms, which were unaffected by prior TNF $\alpha$  administration. (\*\* denotes  $p < 0.01$ ).

	<b>Sham</b>	<b>TNF<math>\alpha</math></b>
Pre challenge	0.4 $\pm$ 0.2	0.6 $\pm$ 0.2
24 hrs post challenge	0.4 $\pm$ 0.2	1.1 $\pm$ 0.3**
Post allergen challenge	5.0 $\pm$ 0.6	5.9 $\pm$ 0.3

## Legends

Fig. 1. Effects of intranasal TNF $\alpha$  and sham challenge on nasal lavage fluid levels of  $\alpha_2$ -macroglobulin in healthy subjects. The challenges were separated by at least seven days. Nasal lavages were carried out before each challenge (pre-challenge) as well as 10 min and 24 hrs thereafter. TNF $\alpha$  produced significant increases in lavage fluid levels of  $\alpha_2$ -macroglobulin 24 hrs post challenge, whereas no such effect was observed at 10 min post challenge. (\*\* denotes  $p < 0.01$ )

Fig. 2. Effects of nasal TNF $\alpha$  and sham challenge on lavage fluid levels of  $\alpha_2$ -macroglobulin (a), IL-8 (b), ECP (c), and MPO (d) in patients with allergic rhinitis examined outside the pollen season. The lavages were carried out before each challenge (pre-challenge) and 24 hrs thereafter (24 hrs). In addition, lavages were carried out 10 min after an allergen challenge that in turn was carried out 24 hrs after the sham/TNF $\alpha$  challenge (24 hrs + allergen). TNF $\alpha$  significantly increased the lavage fluid levels of IL-8, ECP, and  $\alpha_2$ -macroglobulin. An increase in MPO was also observed following TNF $\alpha$ , but this change only reached borderline significance ( $p = 0.09$ ). The responsiveness to allergen was significantly increased following TNF $\alpha$  challenge for MPO (d), but not for the other employed lavage fluid indices. (\* denotes  $p < 0.05$ , \*\* denotes  $p < 0.01$ ).

## References

1. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. *J Dermatolog Treat* 2004;15:280-294.
2. Yu CK, Yang BC, Lee SC, Wang JY, Hsiue TR, Lei HY. Dermatophagoides-farinae-induced pulmonary eosinophilic inflammation in mice. *Int Arch Allergy Immunol* 1997;112:73-82.
3. Kips JC, Tavernier J, Pauwels RA. Tumor necrosis factor causes bronchial hyper-responsiveness in rats. *Am Rev Respir Dis* 1992;145:332-336.
4. Lukacs NW, Strieter RM, Chensue SW, Widmer M, Kunkel SL. TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. *J Immunol* 1995;154:5411-5417.
5. Kim J, McKinley L, Natarajan S, Bolgos GL, Siddiqui J, Copeland S, Remick DG. Anti-tumor necrosis factor-alpha antibody treatment reduces pulmonary inflammation and methacholine hyper-responsiveness in a murine asthma model induced by house dust. *Clin Exp Allergy* 2006;36:122-32.
6. Renzetti LM, Paciorek PM, Tannu SA, Rinaldi NC, Tocker JE, Wasserman MA, Gater PR. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways. *J Pharmacol Exp Ther* 1996;278:847-853.
7. Gosset P, Tsicopoulos A, Wallaert B, Joseph M, Capron A, Tonnel AB. Tumor necrosis factor alpha and interleukin-6 production by human mononuclear phagocytes from allergic asthmatics after IgE-dependent stimulation. *Am Rev Respir Dis* 1992;146:768-774.
8. Costa JJ, Matossian K, Resnick MB, Beil WJ, Wong DT, Gordon JR, Dvorak AM, Weller PF, Galli SJ. Human eosinophils can express the cytokines tumor necrosis

factor-alpha and macrophage inflammatory protein-1 alpha. *J Clin Invest* 1993;91:2673-2684.

9. Finotto S, Ohno I, Marshall JS, Gauldie J, Denburg JA, Dolovich J, Clark DA, Jordana M. TNF-alpha production by eosinophils in upper airways inflammation (nasal polyposis). *J Immunol* 1994;153:2278-2289.

10. Devalia JL, Campbell AM, Sapsford RJ, Rusznak C, Quint D, Godard P, Bousquet J, Davies RJ. Effect of nitrogen dioxide on synthesis of inflammatory cytokines expressed by human bronchial epithelial cells in vitro. *Am J Respir Cell Mol Biol* 1993;9:271-278.

11. Ackerman V, Marini M, Vittori E, Bellini A, Vassali G, Mattoli S. Detection of cytokines and their cell sources in bronchial biopsy specimens from asthmatic patients. Relationship to atopic status, symptoms, and level of airway hyperresponsiveness *Chest* 1994;105:687-696.

12. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. *Nature* 1990;346:274-276.

13. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, Heusser CH, Howarth PH, Holgate ST. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. *Am J Respir Cell Mol Biol* 1994;10:471-480.

14. Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. *Am J Respir Crit Care Med* 1995;152:76-80.

15. Thomas PS, Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. *Thorax* 2002;57:774-778.

16. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, Beckett P, Al Ali M, Chauhan A, Wilson SJ, Reynolds A, Davies DE, Holgate ST. Tumour Necrosis Factor (TNF $\alpha$ ) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. *Thorax* 2005;60:1012-1018.
17. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, Bradding P, Brightling CE, Wardlaw AJ, Pavord ID. Evidence of a role of tumor necrosis factor alpha in refractory asthma. *N Engl J Med* 2006;354:697-708.
18. Ying S, Robinson DS, Varney V, Meng Q, Tcicopoulos A; Moqbel R, Durham SR, Kay AB, Hamid Q. TNF alpha mRNA expression in allergic inflammation. *Clin Exp Allergy* 1991;21:745-750.
19. Bradding P, Mediawake R, Feather IH, Madden J, Church MK, Holgate ST, Howarth PH. TNF alpha is localized to nasal mucosal mast cells and is released in acute allergic rhinitis. *Clin Exp Allergy* 1995;25:406-415.
20. Bensch GW, Nelson HS, Borish LC. Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines. *Ann Allergy Asthma Immunol* 2002;88:457-462.
21. Greiff L, Andersson M, Persson CGA. Nasal secretions/exudations: Collection and approaches to analysis. In: Rogers D, Donnelly L, eds. *Methods in molecular medicine* (Vol. 56): Human airway inflammation. Totowa (NJ). Humana Press Inc., 2001:61-73.
22. Persson CGA, Erjefält JS, Greiff L, Andersson M, Erjefält I, Godfrey RW, Korsgren M, Linden M, Sundler F, Svensson C. Plasma-derived proteins in airway defence, disease and repair of epithelial injury. *Eur Respir J* 1998;11:958-970.
23. Yamagishi S, Ohnishi M, Pawankar R. IL-1 and TNF-alpha-mediated regulation of IL-6, IL-8, and GM-CSF release from cultured nasal epithelial cells. *Nippon Jibiinkoka Gakkai Kaiho* 2000;103:829-835.

24. Douglass JA, Dhami D, Gurr CE, Bulpitt M, Shute JK, Howarth PH, Lindley IJ, Church MK, Holgate ST. Influence of interleukin-8 challenge in the nasal mucosa in atopic and nonatopic subjects. *Am J Respir Crit Care Med* 1994;150:1108-1113.
25. Benson M, Strannegård IL, Strannegård O, Wennergren G. Topical steroid treatment of allergic rhinitis decreases nasal fluid TH2 cytokines, eosinophils, eosinophil cationic protein, and IgE but has no significant effect on IFN-gamma, IL-1beta, TNF-alpha, or neutrophils. *J Allergy Clin Immunol* 2000;106:307-312.

Fig. 1




Fig. 2a




Fig. 2b






Fig. 2c




Fig. 2d

